ATV 1601
Alternative Names: ATV-1601Latest Information Update: 06 Jan 2025
Price :
$50 *
At a glance
- Originator Atavistik Bio
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-akt inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 02 Jan 2025 Atavistik Bio plans a first-in-human clinical trial for Solid tumours, in early 2025
- 23 Oct 2024 Pharmacodynamics and adverse events data from a preclinical study in Solid tumours released by Atavistik Bio
- 15 Oct 2024 Preclinical trials in Solid tumours in USA (PO) (Atavistik Bio pipeline, October 2024)